Lacosamid Fresenius Kabi (Lacosamide)

Lacosamide selectively enhances the slow inactivation of voltage‑gated sodium channels in neurons. This stabilizes the inactive state of the channels, decreasing repetitive firing and neuronal hyper‑excitability that contribute to focal seizure generation.

The prescribed dose of Lacosamid Fresenius Kabi is determined by the treating physician based on the patient’s clinical condition, weight, renal function, and response to therapy. Dosing regimens are individualized and should follow the prescriber’s instructions.

Safety data for lacosamide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow inactivation of sodium channels—differs from many traditional antiepileptics that target fast inactivation. This can provide an alternative option for patients who have inadequate seizure control with other agents, and it is often used as adjunctive therapy alongside other antiepileptics.

Lacosamid Fresenius Kabi should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before administration, allow the product to reach room temperature if required by the clinical protocol.

Lacosamid Fresenius Kabi is given as an intravenous infusion. The infusion rate and duration are set by the prescribing clinician, typically based on the patient’s weight and clinical response. Administration should follow aseptic technique and institutional infusion guidelines.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, suicidal thoughts or behaviors, severe skin reactions, respiratory depression, and rare cases of anaphylaxis. Patients should be monitored closely for these events, especially during initiation and dose adjustments.

Lacosamid is contraindicated in patients with known hypersensitivity to lacosamide or any component of the formulation. Caution is advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or uncontrolled renal failure, and it should be avoided in those where the risk outweighs potential benefit.